%0 Journal Article %A Carmen Martínez-Cué %A Paula Martínez %A Noemí Rueda %A Rebeca Vidal %A Susana García %A Verónica Vidal %A Andrea Corrales %A Juan A. Montero %A Ángel Pazos %A Jesús Flórez %A Rodolfo Gasser %A Andrew W. Thomas %A Michael Honer %A Frédéric Knoflach %A Jose Luis Trejo %A Joseph G. Wettstein %A Maria-Clemencia Hernández %T Reducing GABAA α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome %D 2013 %R 10.1523/JNEUROSCI.1203-12.2013 %J The Journal of Neuroscience %P 3953-3966 %V 33 %N 9 %X Down syndrome (DS) is associated with neurological complications, including cognitive deficits that lead to impairment in intellectual functioning. Increased GABA-mediated inhibition has been proposed as a mechanism underlying deficient cognition in the Ts65Dn (TS) mouse model of DS. We show that chronic treatment of these mice with RO4938581 (3-bromo-10-(difluoromethyl)-9H-benzo[f]imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]diazepine), a selective GABAA α5 negative allosteric modulator (NAM), rescued their deficits in spatial learning and memory, hippocampal synaptic plasticity, and adult neurogenesis. We also show that RO4938581 normalized the high density of GABAergic synapse markers in the molecular layer of the hippocampus of TS mice. In addition, RO4938581 treatment suppressed the hyperactivity observed in TS mice without inducing anxiety or altering their motor abilities. These data demonstrate that reducing GABAergic inhibition with RO4938581 can reverse functional and neuromorphological deficits of TS mice by facilitating brain plasticity and support the potential therapeutic use of selective GABAA α5 NAMs to treat cognitive dysfunction in DS. %U https://www.jneurosci.org/content/jneuro/33/9/3953.full.pdf